Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alfacalcidol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 9/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | PGR | P06401 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | GC | P02774 | 1/20 | 0.82 |
| ▸ | RXRA | P19793 | 1/20 | 0.82 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.82 |
| ▸ | CNR1 | P21554 | 1/20 | 0.82 |
| ▸ | HTR2C | P28335 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.82 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfacalcidol SCHEMBL15262950 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2AGTR1VDRMAPT | |
| Alfacalcidol SCHEMBL10318047 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2AGTR1VDRMAPT | |
| Alfacalcidol SCHEMBL9663443 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2AGTR1VDRMAPT | |
| Alfacalcidol SCHEMBL14112496 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2AGTR1VDRMAPT | |
| Alfacalcidol SCHEMBL6268936 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2AGTR1VDRMAPT | |
| Alfacalcidol SCHEMBL24066856 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2AGTR1VDRMAPT | |
| Alfacalcidol SCHEMBL8750004 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2AGTR1VDRMAPT | |
| Alfacalcidol SCHEMBL20677327 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2AGTR1VDRMAPT | |
| Alfacalcidol SCHEMBL21283513 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2AGTR1VDRMAPT | |
| Alfacalcidol SCHEMBL7780068 | 1.00 | ADORA3 (1.00) | ADORA3SLC6A2AGTR1VDRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190254312-A1 | Vitamin D Compounds and Methods for Preparing Same | VITAMIN DERIVATIVES INC (US) | 2019-08-22 | — | — | US | claimed |
| US-20160345608-A1 | Vitamin D Compounds and Methods for Preparing Same | VITAMIN DERIVATIVES INC (US) | 2016-12-01 | — | — | US | claimed |
| US-20120184514-A1 | VITAMIN D COMPOUNDS AND METHODS FOR PREPARING SAME | Vitamin Derivatives Inc. (US) | 2012-07-19 | — | — | US | claimed |
| US-20140200201-A1 | Enzymatic Production or Chemical Synthesis and Uses for 5,7-Dienes and UVB Conversion Products Thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-07-17 | — | — | US | disclosed |
| US-8703182-B2 | Light-stabilized soft capsule formulations | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-04-22 | — | — | US | disclosed |
| EP-1502588-B1 | LIGHT-STABILIZED SOFT CAPSULE FOR FORMULATIONS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120258938-A1 | Enzymatic Production or Chemical Synthesis and Uses for 5,7-Dienes and UVB Conversion Products Thereof | SLOMINSKI ANDREJ (US) | 2012-10-11 | — | — | US | disclosed |
| US-20110118228-A1 | Enzymatic production or chemical synthesis and uses for 5,7-dienes and UVB conversion products thereof | SLOMINSKI ANDRZEJ | 2011-05-19 | — | — | US | disclosed |
| WO-2011002756-A2 | VITAMIN D COMPOUNDS AND METHODS FOR PREPARING SAME | VITAMIN DERIVATIVES, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100021535-A1 | LIGHT-STABILIZED SOFT CAPSULE FORMULATIONS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20070215455-A1 | Isomerisation of pharmaceutical intermediates | LEO PHARMA A/S (DK) | 2007-09-20 | — | — | US | disclosed |
| US-20070093448-A1 | Complexes that consist of vitamin D compounds or analogs thereof with a 5Z,7E,10(19)-triene system and methylated derivatives of beta-cyclodextrin | SCHERING AG (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20050214361-A1 | Photostabilized soft capsule | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-29 | — | — | US | disclosed |
| US-20050084908-A1 | Methods for detecting binding of low-molecular-weight compound and its binding partner molecule | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2005-04-21 | — | — | US | disclosed |
| EP-1502588-A1 | LIGHT-STABILIZED SOFT CAPSULE FOR FORMULATIONS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-02-02 | — | — | EP | disclosed |
| US-20040248859-A1 | Medicinal compositions for treating secondary parathyroid hyperfunction and remedies for cardiovascular complications in association with treatment for secondary parathyroid hyperfunction | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1402893-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SECONDARY HYPERPARATHYROIDISM AND THERAPEUTIC AGENTS FOR CARDIOVASCULAR COMPLICATIONS RESULTING FROM THE TREATMENT FOR SECONDARY HYPERPARATHYROIDISM. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160345608-A1 | Vitamin D Compounds and Methods for Preparing Same | CYP24A1, VDR, GC | VDR 2/4885ADORA3 604/4885SLC6A2 4780/4885 |
| US-20190254312-A1 | Vitamin D Compounds and Methods for Preparing Same | CYP24A1, VDR, CYP2R1 | VDR 2/4885ADORA3 433/4885SLC6A2 4744/4885 |
| US-20070215455-A1 | Isomerisation of pharmaceutical intermediates | CYP24A1, CYP2R1, VDR | VDR 3/4885ADORA3 339/4885SLC6A2 2901/4885 |
| US-20070093448-A1 | Complexes that consist of vitamin D compounds or analogs thereof with a 5Z,7E,10(19)-triene system and methylated derivatives of beta-cyclodextrin | VDR, CYP24A1, CYP2R1 | VDR 1/4885ADORA3 1997/4885SLC6A2 4636/4885 |
| US-20120184514-A1 | VITAMIN D COMPOUNDS AND METHODS FOR PREPARING SAME | CYP24A1, VDR, GC | VDR 2/4885ADORA3 604/4885SLC6A2 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.